Monitoring Progress Towards the Elimination of Hepatitis C as a Public Health Threat in Norway: A Modelling Study Among People Who Inject Drugs and Immigrants
Open Access
- 27 March 2024
- journal article
- research article
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 230 (3) , e700-e711
Abstract
Background: The global incidence target for the elimination of hepatitis C among people who inject drugs (PWID) is <2/100. In Norway, the hepatitis C epidemic is concentrated in PWID. Immigrants are the second most important risk group for chronic infection. We modelled the incidence of hepatitis C among active PWID, and the prevalence of chronic infection among active PWID, ex-PWID, and immigrants in Norway to 2022. Methods: We built a stochastic compartmental model, which was informed using data from national data sources, literature, and expert opinion. We report median values with 95% credible intervals (CrI). Results: The model estimated 30 (95% Crl, 13–52) new infections among active PWID in 2022, or 0.37/100 (95% Crl, 0.17–0.65), down from a peak of 726 (95% Crl, 506–1067) in 2000. Across all groups, the model estimated 3202 (95% Crl, 1273–6601) chronically infected persons in 2022. Results were robust in sensitivity analyses. Conclusions: Norway provides an example of the feasibility of hepatitis C elimination in a setting with a concentrated epidemic, high coverage of harm reduction services, and no treatment restrictions. Continued momentum is needed to further reduce the transmission and burden of hepatitis C in Norway.Keywords
This publication has 30 references indexed in Scilit:
- Towards elimination of hepatitis C in Oslo: Cross-sectional prevalence studies among people who inject drugsInternational Journal of Drug Policy, 2023
- Hepatitis C treatment uptake among people who inject drugs in Oslo, Norway: A registry-based studyInternational Journal of Drug Policy, 2023
- Global coverage of interventions to prevent and manage drug-related harms among people who inject drugs: a systematic reviewThe Lancet Global Health, 2023
- Worldwide prevalence of hepatitis B virus and hepatitis C virus among patients with cirrhosis at country, region, and global levels: a systematic reviewThe Lancet Gastroenterology & Hepatology, 2022
- Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling studyThe Lancet Gastroenterology & Hepatology, 2022
- Methods and indicators to validate country reductions in incidence of hepatitis C virus infection to elimination levels set by WHOThe Lancet Gastroenterology & Hepatology, 2022
- Hepatitis C treatment and reinfection surveillance among people who inject drugs in a low-threshold program in Oslo, NorwayInternational Journal of Drug Policy, 2021
- The contribution of injection drug use to hepatitis C virus transmission globally, regionally, and at country level: a modelling studyThe Lancet Gastroenterology & Hepatology, 2019
- Estimating incidence of problem drug use using the Horwitz-Thompson estimator – A new approach applied to people who inject drugs in Oslo 1985–2008International Journal of Drug Policy, 2016
- Natural history of hepatitis CJournal of Hepatology, 2014